LEADER 01764nam  2200421Ia 450 
001 9910698365003321
005 20071004114958.0
035   $a(CKB)4970000000031305
035   $a(OCoLC)173661664
035   $a(EXLCZ)994970000000031305
100   $a20071004d2007      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFood and Drug Administration$b[electronic resource] $emethodologies for identifying and allocating costs of reviewing medical device applications are consistent with federal cost accounting standards, and staffing levels for reviews have generally increased in recent years
210  1$aWashington, DC :$cU.S. Govt. Accountability Office,$d[2007]
215   $a13 pages $cdigital, PDF file
300   $aTitle from title screen (viewed on Sept. 17, 2007).
300   $aAuthor: Robert E. Martin.
300   $a"June 25, 2007."
300   $aPaper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
300   $a"GAO-07-882R."
320   $aIncludes bibliographical references.
517   $aFood and Drug Administration
606   $aUser charges$xGovernment policy$zUnited States
606   $aMedical instruments and apparatus industry$xGovernment policy$zUnited States
615  0$aUser charges$xGovernment policy
615  0$aMedical instruments and apparatus industry$xGovernment policy
700   $aMartin$b Robert E$0191274
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aDOCUMENT
912   $a9910698365003321
996   $aFood and Drug Administration$93471805
997   $aUNINA